Arkansas Center for Advancing Pediatric Therapeutics (ArCAPT)

阿肯色州儿科治疗促进中心 (ArCAPT)

• 批准号: 9262528
• 负责人: Laura P James
• 金额: $ 6.91万
• 依托单位: ARKANSAS CHILDREN'S HOSPITAL RES INST
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-21 至 2016-09-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9262528
• 关键词: Address; Adolescent; Adult; Age; Area; Arkansas; Caliber; Capital; Child; Child health care; Childhood; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Network; Coin; Conduct Clinical Trials; Country; Data; Development; Disease; Education; Environment; Environmental Exposure; Environmental Risk Factor; Ethnic Origin; Funding; Future; Goals; Gold; Growth; Health; Health Status; Infant; Intervention; Knowledge; Life; Link; Lung diseases; Medical; Medicine; Neurodevelopmental Disorder; Obesity; Orphan; Outcome; Patients; Pediatric Hospitals; Pediatrics; Perinatal; Pharmaceutical Preparations; Population; Prediabetes syndrome; Process; Race; Research; Research Ethics; Research Infrastructure; Research Institute; Research Personnel; Research Support; Resources; Rights; Science; Statutes and Laws; Testing; Therapeutic; Therapeutic Trials; Training; Translations; United Nations; United States; United States National Institutes of Health; Universities; Work; base; burden of illness; clinical investigation; design; effective therapy; ethnic minority population; evidence base; improved; innovation; inter-institutional; investigator training; minority health; neurodevelopment; new technology; next generation; novel therapeutics; pediatric patients; postnatal; programs; racial minority; research clinical testing; symposium; tool; treatment response; trial design

PROJECT SUMMARY The vast majority of research conducted in children in the United States (US) today does not include children living in the 24 IDeA eligible states/territories identified by the NIH such as Arkansas. Consequently, findings may not be generalizable to a substantial proportion of children who carry the highest disease burdens such as obesity, diabetes, pre-maturity, lung and neurodevelopmental disorders. Future therapeutic and non- therapeutic trials must be available to these children if their health status is to be improved. Arkansas Children's Research Institute (ACRI) is prepared to immediately address the overarching program goals of the IDeA States Pediatric Clinical Trial Network (ISPCTN) and thereby, work to close the “clinical trial gap” for children living in IDeA states. To this end, we have formed the Arkansas Center for Advancing Pediatric Therapeutics (ArCAPT). Our efforts will be directed by the central hypothesis that ArCAPT will enable the participation of diverse groups of infants, children and adolescents in expertly designed, innovative clinical trials of the highest quality and scientific value. We will leverage our unique patient base, intellectual capital and established inter-institutional resources to enhance pediatric clinical trials funded by the NIH and other supported research. Our established clinical trial enterprise and cadre of senior pediatric clinical investigators will enable us to explore the impact and intersection of ontogeny, environmental exposure and disease in four high priority areas: upper and lower airway disease; obesity; neurodevelopment and pre-, peri- and postnatal development. Our hypothesis will be tested by executing three specific aims: 1) Link established inter- and intra-institutional resources supporting pediatric clinical trials. We will partner with Arkansas Children's Hospital and the University of Arkansas for Medical Sciences to increase the scope of pediatric trials, address the impact of racial and ethnic minority health issues and the intersection of environmental factors and disease as they relate to therapeutic endpoints. 2). Provide supervised professional development in research and clinical trial implementation. We will maintain and expand our existing clinical research teams and train the next generation of pediatric clinical researchers through high quality education in the conduct of pediatric clinical trials. 3). Create a state-of-the-art clinical trial platform for infants, children and adolescents. Using a cross-disciplinary team involving multiple pediatric subspecialists, we will expand clinical research and test and validate new technologies, tools and approaches for evaluating the interface between race/ethnicity, ontogeny, environment, disease and treatment response. The outcome of this proposal will improve the health of children of Arkansas and beyond by systematically addressing the unique health challenges of IDeA state populations.

项目概要 目前在美国针对儿童进行的绝大多数研究并不包括儿童 居住在 NIH 确定的 24 个符合 IDeA 条件的州/地区，例如阿肯色州。因此，研究结果 可能无法推广到大部分疾病负担最高的儿童，例如 肥胖、糖尿病、早产、肺和神经发育障碍。未来的治疗性和非 如果要改善这些儿童的健康状况，就必须对其进行治疗试验。阿肯色州 儿童研究所 (ACRI) 准备立即解决该项目的总体计划目标 IDeA 建立了儿科临床试验网络 (ISPCTN)，从而努力缩小儿童的“临床试验差距” 生活在 IDeA 州的儿童。为此，我们成立了阿肯色州儿科促进中心 治疗学（ArCAPT）。我们的努力将以 ArCAPT 将使 不同群体的婴儿、儿童和青少年参与精心设计、创新的活动 最高质量和科学价值的临床试验。我们将利用我们独特的患者基础， 智力资本和已建立的机构间资源，以加强由儿童基金会资助的儿科临床试验 NIH 和其他支持的研究。我们建立的临床试验企业和高级儿科临床骨干队伍 研究人员将使我们能够探索个体发育、环境暴露和 四个高度优先领域的疾病：上呼吸道疾病和下呼吸道疾病；肥胖;神经发育和前期、后期 和产后发育。我们的假设将通过执行三个具体目标来检验：1）链接 建立支持儿科临床试验的机构间和机构内资源。我们将合作 与阿肯色州儿童医院和阿肯色州医学科学大学合作，扩大 儿科试验，解决种族和少数族裔健康问题以及交叉问题的影响 与治疗终点相关的环境因素和疾病。 2）。提供监督 研究和临床试验实施方面的专业发展。我们将维持并扩大我们的 现有的临床研究团队，并通过高水平培训下一代儿科临床研究人员 进行儿科临床试验的质量教育。 3）。打造一流的临床试验平台 适合婴儿、儿童和青少年。使用涉及多名儿科人员的跨学科团队 我们将扩大临床研究并测试和验证新技术、工具和方法 用于评估种族/民族、个体发育、环境、疾病和治疗反应之间的界面。 该提案的结果将通过系统地改善阿肯色州及其他地区儿童的健康 解决 IDeA 州人口独特的健康挑战。